About this trial
The purpose of the ARCH study is to find out whether immunotherapy with cemiplimab helps reduce
the chance of lung cancer recurring after surgery, if chemotherapy cannot be given.
Patients who participate in the ARCH study have had their lung cancer removed by surgery before they start the study. Their lung cancer has the PD-L1 molecule. During the ARCH study, patients will either receive 10 cycles of immunotherapy with cemiplimab or no drug therapy as
part of this study.
Patient Profile
For patients with early-stage non-small cell lung cancer (NSCLC) that has been removed by surgery and who have not been treated with chemotherapy after surgery
Where’s this trial being run?
Beaumont Hospital and St James’s Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | ETOP ARCH |
|---|---|
| Number: | 25-24 |
| Full Title: | A randomised phase III trial of adjuvant cemiplimab in patients with resected stage II-IIIA NSCLC who have not received prior adjuvant chemotherapy |
| Principal Investigator: | Prof Patrick Forde (SJH) |
|---|---|
| Type: | Collaborative |
| Sponsor: | ETOP IBCSG Partners Foundation |
| Recruitment Started: |
Global: Ireland: Dec 25 |
| Global Recruitment Target: | 390 |
|---|---|
| Ireland Recruitment Target: | 50 |